SHINE Technologies LLC, a Janesville-based next-generation fusion technology company, announced that the U.S. Nuclear Regulatory Commission (NRC) has issued its final safety evaluation report for SHINE’s large-scale medical isotope production facility, The Chrysalis, in Janesville, which concludes that the technical requirements for issuing an operating license have been met.
SHINE’s operating license application was filed with the NRC in July 2019. The company submitted its construction permit application to the NRC in 2013 and was granted that permit in 2016.
In the process of supporting the technical review for the final safety evaluation report related to the operating license application, SHINE responded to more than 300 formal requests for additional information and participated in regulatory audits on more than two dozen topics. After meeting with SHINE over a total of 11 days in 2022, the NRC’s Advisory Committee on Reactor Safeguards, in a letter to the Commission, recommended issuance of the operating license.
Production equipment will continue to be installed in The Chrysalis as SHINE keeps the NRC apprised of construction progress. Upon completion of operational readiness inspections, the NRC will decide on the issuance of an operating license.
When The Chrysalis is fully operational, the company plans to produce medical isotopes, including molybdenum-99, which powers more than 40 million medical procedures annually to diagnose heart disease, cancer, and other diseases.
